122 related articles for article (PubMed ID: 9816277)
1. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F
Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
Wedge SR; Laohavinij S; Taylor GA; Boddy A; Calvert AH; Newell DR
Clin Cancer Res; 1995 Dec; 1(12):1479-86. PubMed ID: 9815947
[TBL] [Abstract][Full Text] [Related]
3. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
[TBL] [Abstract][Full Text] [Related]
5. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Johansen M; Zukowski T; Hoff PM; Newman RA; Ni D; Hutto T; Abbruzzeese J; Berghorn E; Hausheer F; Madden T
Cancer Chemother Pharmacol; 2004 May; 53(5):370-6. PubMed ID: 15060739
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG
J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744
[TBL] [Abstract][Full Text] [Related]
7. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.
Synold TW; Newman EM; Carroll M; Muggia FM; Groshen S; Johnson K; Doroshow JH
Clin Cancer Res; 1998 Oct; 4(10):2349-55. PubMed ID: 9796964
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors.
Thödtmann R; Depenbrock H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
Semin Oncol; 1999 Apr; 26(2 Suppl 6):89-93. PubMed ID: 10598561
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
Erba E; Sen S; Sessa C; Vikhanskaya FL; D'Incalci M
Br J Cancer; 1994 Feb; 69(2):205-11. PubMed ID: 8297715
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.
Alati T; Worzalla JF; Shih C; Bewley JR; Lewis S; Moran RG; Grindey GB
Cancer Res; 1996 May; 56(10):2331-5. PubMed ID: 8625328
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Salazar R; Bissett D; Twelves C; Breimer L; DeMario M; Campbell S; Zhi J; Ritland S; Cassidy J
Clin Cancer Res; 2004 Jul; 10(13):4374-82. PubMed ID: 15240525
[TBL] [Abstract][Full Text] [Related]
15. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
[TBL] [Abstract][Full Text] [Related]
16. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
19. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
